Theseus Pharmaceuticals, Inc.
THRX evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Lead Asset:
- THE-630 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for THRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
THE-630 (Phase 1/Phase 2)
Next Catalyst
—
Tracking 1 pipeline candidate for Theseus Pharmaceuticals, Inc..
Run Theseus Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Theseus Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Theseus Pharmaceuticals, Inc.'s lead drug candidate?
Theseus Pharmaceuticals, Inc.'s most advanced tracked candidate is THE-630 (Phase 1/Phase 2) for Gastrointestinal stromal tumors (GIST).
Who is the CEO of Theseus Pharmaceuticals, Inc.?
Chief Executive Officer is the chief executive officer of Theseus Pharmaceuticals, Inc. (THRX).
What therapeutic areas does Theseus Pharmaceuticals, Inc. focus on?
Theseus Pharmaceuticals, Inc. develops therapies across Oncology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.